Read by QxMD icon Read


Rosario Palacios, M Mayorga, C M González-Domenech, C Hidalgo-Tenorio, C Gálvez, L Muñoz-Medina, J de la Torre, A Lozano, M Castaño, M Omar, Jesús Santos
OBJECTIVES: To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART). METHODS: Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed. RESULTS: A total of 104 participants were included, who switched for the following reasons: toxicity/intolerance (42...
January 2018: Journal of the International Association of Providers of AIDS Care
Amedeo Ferdinando Capetti, Maria Vittoria Cossu, Gaetana Sterrantino, Giorgio Barbarini, Simona Di Giambenedetto, Giuseppe Vittorio De Socio, GianCarlo Orofino, Antonio Di Biagio, Benedetto M Celesia, Stefano Rusconi, Barbara Argenteri, Giuliano Rizzardini
BACKGROUND: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients. OBJECTIVE: The primary objective is to report the 96-week virological suppression in our cohort, assessing the durability of this strategy in complicated situations. The secondary objective is to describe the safety and metabolic profile. METHODS: All patients who had switched to DTG plus RPV between October 1, 2014, and September 30, 2015, were analyzed using a retrospective-prospective design, approved by ethics committees...
February 1, 2018: Annals of Pharmacotherapy
Ji Li, Hong Lai, Shaoguang Chen, Shenghan Lai
Previous studies have demonstrated a link between protease inhibitor (PI)-based therapy and lipid dysregulation. The main objective of this study was to examine whether cocaine use may modify PI-associated dyslipidemia in adults. Between June 2003 and June 2014, 957 human immunodeficiency virus (HIV)-infected participants in Baltimore, Maryland were enrolled in a study that investigated HIV/antiretroviral therapy-associated comorbidities. Multiple linear and logistic regression models were fitted to examine the associations between PI therapy and lipid profiles for the pooled sample and cocaine use subgroups, respectively...
January 1, 2018: International Journal of STD & AIDS
Catalin Tiliscan, Victoria Arama, Raluca Mihailescu, Daniela Munteanu, Diana Gabriela Iacob, Cristina Popescu, Remulus Catana, Anca Negru, Alina Lobodan, Stefan Sorin Arama
BACKGROUND: Adiponectin and leptin are adipose tissue hormones that regulate important lipid and glucose metabolic pathways. Our objective was to evaluate the interplay of these hormones described by the adiponectin/leptin ratio (ALR) in correlation to lipid and carbohydrate metabolism parameters in nondiabetic HIV-infected patients during antiretroviral therapy (ART). MATERIALS AND METHODS: We enrolled consecutive nondiabetic patients with confirmed HIV infection, undergoing stable ART regimens for at least six months...
February 16, 2018: Endocrine Research
Marcelo Nardi Pedro, Daniela Oliveira Magro, Elizabete Urbano Pinaço Pinto da Silva, Dioze Guadagnini, Andrey Santos, Rogerio de Jesus Pedro, Mario José Abdalla Saad
Background: In HIV patients using HAART insulin resistance is a central pathophysiological condition that can contribute to the development of diabetes and cardiovascular complications. To examine the role of adipocyte hormones and LPS in insulin resistance in HIV patients, we investigated the role of adiponectin, leptin, visfatin and LPS levels in the insulin resistance of HIV-infected patients treated with HAART. Methods: This study included 67 HIV positive individuals on HAART and ten healthy controls...
2018: Diabetology & Metabolic Syndrome
Magdalena Rogalska-Płońska, Anna Grzeszczuk, Paweł Rogalski, Mariusz Łucejko, Robert Flisiak
BACKGROUND: Metabolic syndrome (MS) is usually diagnosed based on presence of abdominal obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides (TG) and low high-density lipoprotein levels (HDL). Whether HIV is associated with a higher prevalence of metabolic syndrome than general population remains unclear. AIM: Aim of the study was to determine the incidence of metabolic syndrome in the population of HIV infected adults and its association with clinical, virological and biochemical features...
January 19, 2018: Kardiologia Polska
Luiz Rodrigo Augustemak de Lima, Edio Luiz Petroski, Yara Maria Franco Moreno, Diego Augusto Santos Silva, Erasmo Benício de Moraes Santos Trindade, Aroldo Prohmann de Carvalho, Isabela de Carlos Back
HIV-infected children and adolescents may be at risk for cardiovascular disease due to chronic inflammation and exacerbation of risk factors. The aim of this study was as follows: 1) compare cardiovascular risk factors, chronic inflammation, and carotid intima-media thickness (IMTc) between the HIV and control groups; 2) determine the association of HIV and antiretroviral (ART) regimens with cardiovascular risk factors, chronic inflammation, and IMTc; and 3) identify variables associated with elevated IMTc...
2018: PloS One
Esther Rodríguez-Gallego, Josep Gómez, Yolanda María Pacheco, Joaquim Peraire, Consuelo Viladés, Raúl Beltrán-Debón, Roger Mallol, Miguel López-Dupla, Sergi Veloso, Verónica Alba, Julià Blanco, Nicolau Cañellas, Anna Rull, Manuel Leal, Xavier Correig, Pere Domingo, Francesc Vidal
OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after ART in order to envisage the underlying mechanistic pathways that influence the treatment response. DESIGN: This was a multi-centre, prospective cohort study in ART-naïve and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64)...
December 26, 2017: AIDS
M Floridia, G Masuelli, M Ravizza, B Tassis, I Cetin, M Sansone, A Degli Antoni, G Simonazzi, A Maccabruni, D Francisci, V Frisina, G Liuzzi, S Dalzero, E Tamburrini
Background: Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparative data in pregnant women are limited. We assessed the safety and activity profile of these two drugs in pregnancy using data from a national observational study. Methods: Women with atazanavir or darunavir exposure in pregnancy were evaluated for laboratory measures and main pregnancy outcomes (e.g. preterm delivery, low birthweight, non-elective caesarean section and neonatal gestational age-adjusted birthweight Z-score)...
April 1, 2018: Journal of Antimicrobial Chemotherapy
Gebremedhin Gebremicael, Yemane Amare, Feyissa Challa, Atsbeha Gebreegziabxier, Girmay Medhin, Mistire Wolde, Desta Kassa
Background: Understanding whether the preceding low lipid profile leads to active tuberculosis (TB) or active TB leads to low lipid profile is crucial. Methods: Lipid profile concentrations were determined from 159 study participants composed of 93 active TB patients [44 HIV coinfected (HIV+TB+) and 49 HIV negative (HIV-TB+)], 41 tuberculin skin test (TST) positive cases [17 HIV coinfected (HIV+TST+) and 24 HIV negative (HIV-TST+)], and 25 healthy controls (HIV-TST-)...
2017: International Journal of Chronic Diseases
C Padmapriyadarsini, Anita Shet, R Srinivasan, Geetha Ramachandran, G N Sanjeeva, Poornaganga Devi, K Ramesh, Perumal K Bhavani, Devaraj Reddy, E Suresh, C Chandrasekhar, Christine Wanke, Soumya Swaminathan
BACKGROUND: As large numbers of children are accessing antiretroviral therapy (ART) in India, we evaluated the dietary intake, growth pattern and risk of metabolic complications like dyslipidemia and insulin resistance among ART-naïve HIV-infected children (CLHIV). METHODS: CLHIV 2-12 years of age, at the time of initiating ART in Chennai and Bangalore, were assessed for their dietary intake, anthropometry, blood CD4 cell count, HIV-1 viral load, fasting serum lipids, glucose and insulin...
March 2018: Pediatric Infectious Disease Journal
Mariana Amaral Raposo, Geyza Nogueira de Almeida Armiliato, Nathalia Sernizon Guimarães, Camila Abrahão Caram, Raíssa Domingues de Simoni Silveira, Unaí Tupinambás
INTRODUCTION: Metabolic disorders in people living with HIV/AIDS (PLH) have been described even before the introduction of antiretroviral (ARV) drugs in the treatment of HIV infection and are risk factors for cardiovascular diseases. Based on this, the purpose of this study was to assess metabolic disorders and cardiovascular risk in PLH before the initiation of antiretroviral treatment (ART). METHODS: This was a cross-sectional descriptive study of 87 PLH without the use of ART, which was carried out between January and September 2012 at a specialized infectious diseases center in Minas Gerais, Brazil...
September 2017: Revista da Sociedade Brasileira de Medicina Tropical
Rebeca Antunes Beraldo, André Pereira Dos Santos, Mariana Palma Guimarães, Helena Siqueira Vassimon, Francisco José Albuquerque de Paula, Dalmo Roberto Lopes Machado, Maria Cristina Foss-Freitas, Anderson Marliere Navarro
INTRODUCTION: The HIV lipodystrophy syndrome is characterized by changes in metabolism, and body composition that increase cardiovascular risk of people living with HIV/AIDS (PLWHA) using highly active antiretroviral therapy (HAART). OBJECTIVE: To assess the prevalence of lipodystrophy and changes in lipid and glucose metabolism in PLWHA in use of HAART. METHODS: For the anthropometric evaluation we measured weight, height and abdominal circumference (AC)...
July 2017: Revista Brasileira de Epidemiologia, Brazilian Journal of Epidemiology
J Jao, W Yu, K Patel, T L Miller, B Karalius, M E Geffner, L A DiMeglio, A Mirza, J S Chen, M Silio, E J McFarland, R B Van Dyke, D Jacobson
OBJECTIVES: Dyslipidaemia is common in perinatally HIV-infected (PHIV) youth receiving protease inhibitors (PIs). Few studies have evaluated longitudinal lipid changes in PHIV youth after switch to newer PIs. METHODS: We compared longitudinal changes in fasting lipids [total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and TC:HDL-C ratio] in PHIV youth enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) study who switched to atazanavir/ritonavir (ATV/r)- or darunavir/ritonavir (DRV/r)-based antiretroviral therapy (ART) from an older PI-based ART and those remaining on an older PI...
March 2018: HIV Medicine
Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virologically suppressed, HIV-infected patients. METHODS: Retrospective analysis of patients who started rilpivirine or an InSTI (both with tenofovir and emtricitabine) with <50 HIV-RNA copies/mL and had at least one HIV-RNA assessed while receiving the study regimen...
November 16, 2017: BMC Infectious Diseases
José M Gatell, Lambert Assoumou, Graeme Moyle, Laura Waters, Margaret Johnson, Pere Domingo, Julie Fox, Esteban Martinez, Hans-Jürgen Stellbrink, Giovanni Guaraldi, Mar Masia, Mark Gompels, Stephane De Wit, Eric Florence, Stefan Esser, François Raffi, Anton L Pozniak
OBJECTIVE: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. METHODS: HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. Patients were randomized to switch to DTG or to remain on PI/r. Primary endpoints were: proportion maintaining HIV RNA less than 50 copies per ml and percentage change from baseline of total cholesterol at week 48...
November 28, 2017: AIDS
H Huff, A T Merchant, E Lonn, E Pullenayegum, F Smaill, M Smieja
OBJECTIVES: Based on a growing body of evidence implicating low vitamin D status in the development of cardiovascular disease (CVD), we hypothesized that in Canadian HIV-positive adults, low 25-hydroxyvitamin D (25(OH)D) concentration would be associated with increased subclinical vascular disease progression. METHODS: We prospectively studied the relationship between baseline 25(OH)D and subsequent progression of carotid intima-media thickness (CIMT) between 2002 and 2011, in the Canadian HIV Vascular Study using stored blood specimens...
November 6, 2017: HIV Medicine
Akshata Mirajkar, Shashikant Nikam, Padmaja Nikam, Giridhar Patil
Human immunodeficiency virus (HIV) infection is a growing concern for health workers. The two major components of dyslipidemia in HIV infected patients are hypertriglyceridemia and decreased levels of high density lipoprotein (HDL) which contribute to increased atherosclerotic risk. The study included 150 newly diagnosed HIV patients and 150 healthy controls. In all these cases Lecithin cholesterol acyl transferase (LCAT) activity was assessed by measuring the difference between esterified and free cholesterol by digitonin precipitation method and levels of Apolipoprotein A-I (apo A-I) were measured by immunoturbidimetric method...
October 2017: Indian Journal of Clinical Biochemistry: IJCB
Federico Pulido, Esteban Ribera, María Lagarde, Ignacio Pérez-Valero, Rosario Palacios, José A Iribarren, Antoni Payeras, Pere Domingo, José Sanz, Miguel Cervero, Adrián Curran, Francisco J Rodríguez-Gómez, María J Téllez, Pablo Ryan, Pilar Barrufet, Hernando Knobel, Antonio Rivero, Belén Alejos, María Yllescas, José R Arribas
Background: Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression. Methods: This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA <50 copies/mL for 6 months or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) and with no resistance were randomized to continue therapy (n = 128) or switch to darunavir/ritonavir and lamivudine (n = 129)...
November 29, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Chloe Orkin, Jean-Michel Molina, Eugenia Negredo, José R Arribas, Joseph Gathe, Joseph J Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer
BACKGROUND: Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate. METHODS: EMERALD was a phase-3, randomised, active-controlled, open-label, international, multicentre trial, done at 106 sites across nine countries in North America and Europe...
October 5, 2017: Lancet HIV
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"